Jeena Sikho Lifecare Reports Robust FY26 Financials, Recommends Dividend

Revenue (FY26): ₹801.35 crore
Profit After Tax (FY26): ₹222.18 crore

Reader Takeaway: Strong FY26 growth and margins; monitor quarterly margin fluctuations and expansion strategy.

What just happened

Jeena Sikho Lifecare Limited announced its financial results for the fourth quarter and full fiscal year ended March 31, 2026. The company reported a significant year-on-year growth in revenue and profit. For the full fiscal year FY26, revenue stood at ₹801.35 crore, with a profit after tax of ₹222.18 crore. In the fourth quarter (Q4FY26), revenue was ₹215.55 crore, marking a 55% increase from ₹139.25 crore in Q4FY25.

Why this matters

The strong financial performance, especially the significant revenue growth and improved full-year EBITDA margin, indicates healthy operational performance and expanding market reach. The recommended dividend of ₹4.50 per equity share signals the company's positive outlook and commitment to shareholder returns.

The backstory

Jeena Sikho Lifecare operates healthcare facilities, with a focus on expanding its regional presence. The company manages a significant number of operational beds, aiming to increase asset utilization and introduce new products.

What changes now

With the strong FY26 performance and recommended dividend, the company aims to build on this momentum. The focus remains on regional penetration, optimizing existing assets, and launching new products in the over-the-counter (OTC) segment.

Risks to watch

The company's EBITDA margin saw a sequential dip in Q4FY26 to 36% from 45% in Q3FY26. Management attributed this to year-end provisions, including those for labor code amendments, ESOPs, and performance bonuses. Investors should monitor the sustainability of margins amidst these provisioning impacts and operational costs.

Peer comparison

While specific peer data is not provided in the filing, Jeena Sikho Lifecare highlighted its 3-year average Return on Capital Employed (ROCE) of 46%, suggesting capital efficiency. The company's reported full-year EBITDA margin of 44% for FY26 indicates strong operational leverage and efficiency.

Context metrics

• FY26 Revenue: ₹801.35 crore
• FY26 Profit After Tax: ₹222.18 crore
• Q4FY26 Revenue: ₹215.55 crore (up 55% YoY)
• Q4FY26 EBITDA Margin: 36%
• FY26 EBITDA Margin: 44% (up from 30% in FY25)
• Operational Beds: 2,300
• Recommended Dividend: ₹4.50 per equity share

What to track next

Investors will be keen to track the company's ability to maintain its revenue growth trajectory, sustain its improved full-year EBITDA margins, and successfully execute its expansion plans, including the launch of new OTC products.